BTIG analyst Ryan Zimmerman downgraded RxSight (RXST) to Neutral from Buy without a price target The firm cites the “another quarter of weak” of preliminary results due to declining utilization and “extremely soft” Light Delivery Device sales for the downgrade. RxSight’s inability to navigate challenges along with a the need to readjust its sales processes suggests a drawn-out recovery, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Closing Bell Movers: AES Corp jumps 14% on takeover possibility
- RxSight cuts FY25 revenue view to $120M-$130M from $160M-$175M
- RxSight sees Q2 revenue $33.6M, consensus $39.78M